Bayer announced its acquisition of portfolio company Perfuse Therapeutics to complement its ophthalmology pipeline.
Perfuse Therapeutics is a clinical-stage biopharmaceutical company committed to reducing the incidence of blindness through novel therapeutics targeting ocular diseases
Perfuse Therapeutics is a clinical-stage biopharmaceutical company committed to reducing the incidence of blindness through novel therapeutics targeting ocular diseases. The company is pioneering a first-in-class endothelin antagonist to improve retinal blood flow and prevent vision loss in conditions like glaucoma and diabetic retinopathy.